Diabetes

President and CEO Kevin Sayer said the company will file for Medicare coverage of the G6, while it continues to work out an issue that prevents beneficiaries from using a feature that lets data be displayed or shared on cell phones.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included final numbers for 2018 enrollment in Affordable Care Act plans; an increase in Medicare Advantage payments; National Public Health Week highlighted the importance of community relationships in improving health.

Sanofi, 1 of 3 drug manufacturers embroiled in a lawsuit involving insulin prices, said Thursday it is offering a discount program for some patient with diabetes who are uninsured or who have high-deductible insurance plans.

Rapid progression of diabetes complications was associated with higher risk of severe hypoglycemia.

The insurer's chief medical officer reports that the CDC metric is proving useful over time.

Some Medicare Advantage plans may not be fully ready for the requirements of this history-making preventive service.

A commentary from our editor-in-chief on the recent guidance from the American College of Physicians regarding glycemic control for adults with type 2 diabetes.

This study evaluated a pharmacist-managed diabetes clinic to determine its impact on diabetes-related quality measures.(For Tables and Figures, please access the PDF on last page.)

Enrollment, claims, and spatial data are used to demonstrate the importance of outreach strategies for families in rural areas who have children with diabetes. Spatial barriers, alone, do not fully elucidate racial/ethnic disparities in pediatric diabetes for street-level location. (For Tables and the Figure, please access the PDF on the last page.)

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Science 37 hopes to help researchers produce clinical trial results that are closer to real-world experiences, for the benefit of patients, pharma, and payers.

Missed sessions are the obvious place where digital programs can find a place in the launch of Medicare's first fully reimbursed preventive service.

After taking recommendations from providers, Mississippi lawmakers pass a bill that would end caps on prescription drugs and office visits in Medicaid.

This week, the top managed care stories included another insurer announcing it would pass on drug rebates to consumers; FDA approved a new continuous glucose monitor and created a new medical device class; new guidelines address how to treat people with both HIV and cancer.

With Medicaid consuming a larger share of the Mississippi's budget, innovative solutions were needed to deliver improved health outcomes at a lower cost. A public-private partnership was created to pursued a population health strategy aimed at reducing preterm births and preventing the progression of prediabetes to type 2 diabetes.

Brenda Schmidt, CEO of Solera Health, discusses how Solera has been getting ready for the launch of the Medicare Diabetes Prevention Program on April 1, 2018.

In a 2-pronged move, the FDA approved the sale of the Dexcom G6 integrated continuous glucose monitoring system for determining blood glucose levels and also classified the unit as a class II medical device, enabling a speedier review for similar future systems.

The lead researcher said the study could lead to women being given a statin as soon as they are diagnosed with endometrial cancer.

A case filed more than a year ago has taken many turns, landing in a federal court in Trenton, where it has been shaped by a difference of opinion over how to address the role of pharmacy benefit managers (PBMs).

Adherence may play a role in the real-world findings of the study, which was sponsored by Janssen.

The study compared patients taking semaglutide with those taking placebo and liraglutide, which is approved for treatment of obesity.

New health statistics from the US government paint a picture of a population that is more obese and more prone to diabetes than it was 20 years ago. On the bright side, however, more people have health insurance.